Clear Cell Adenocarcinoma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A malignant neoplasm composed of glandular epithelial clear cells. Various architectural patterns may be seen, including papillary, tubulocystic, and solid. 
Clear cell adenocarcinomas most frequently harbor alterations in VHL, PBRM1, SETD2, BAP1, and TP53 .
VHL Mutation, PBRM1fs, PBRM1 Mutation, SETD2 Mutation, and TP53 Mutation are the most common alterations in clear cell adenocarcinoma .
There is 1 clinical trial for clear cell adenocarcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains clear cell adenocarcinoma as an inclusion criterion, 1 is phase 2 (1 open).
Ipilimumab and nivolumab are the most common interventions in clear cell adenocarcinoma clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.